ArticleFrontiers in oncology2025
Case Report: Pitfalls in bone marrow evaluation: importance of adequate bone marrow sampling.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone marrow evaluation is a powerful diagnostic tool, but it comes with several potential pitfalls. These include issues related to sampling errors, technical challenges during processing, and misinterpretation of the findings due to similarities between various diseases. Awareness of these pitfalls, adopting a systematic approach of reviewing the bone marrow samples, and carefully integrating clinical information are critical to ensuring accurate diagnosis. Using ancillary techniques, such as immunohistochemistry (IHC), can further aid in distinguishing between benign reactive changes and malignant processes, reducing the likelihood of diagnostic errors. Bone marrow sampling is inherently challenging, and improper or inadequate sampling is one of the most common reasons for diagnostic failure. Moreover, the process of collecting and preparing the bone marrow samples, leading to aspicular aspirate smears with hemodilution, or tissue preparation techniques like decalcification procedures in the core biopsy, leading to IHC stain failures, may add to the diagnostic challenges in bone marrow evaluation. Lastly, inherent properties of some diseases or the presentation of abnormal findings with focal involvement or obscuring of morphology in an inflammatory background can pose a potential diagnostic challenge. In this article, we present three diagnostically challenging cases that highlight potential pitfalls in bone marrow evaluation, along with a brief review of the literature, and describe strategies to avoid diagnostic errors based on our institutional experience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.